Advanced

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

Fleisher, Mark; Marsal, Jan LU ; Lee, Scott D.; Frado, Laura E.; Parian, Alyssa; Korelitz, Burton I. and Feagan, Brian G. (2018) In Digestive Diseases and Sciences 63(4). p.825-833
Abstract

Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who... (More)

Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Crohn’s disease, Extraintestinal manifestations, Inflammatory bowel disease, Ulcerative colitis
in
Digestive Diseases and Sciences
volume
63
issue
4
pages
825 - 833
publisher
Springer
external identifiers
  • scopus:85042533542
ISSN
0163-2116
DOI
10.1007/s10620-018-4971-1
language
English
LU publication?
yes
id
bf1f73eb-0b87-4c75-9732-332901ac9e85
date added to LUP
2018-03-23 13:53:10
date last changed
2019-03-24 04:45:15
@article{bf1f73eb-0b87-4c75-9732-332901ac9e85,
  abstract     = {<p>Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.</p>},
  author       = {Fleisher, Mark and Marsal, Jan and Lee, Scott D. and Frado, Laura E. and Parian, Alyssa and Korelitz, Burton I. and Feagan, Brian G.},
  issn         = {0163-2116},
  keyword      = {Crohn’s disease,Extraintestinal manifestations,Inflammatory bowel disease,Ulcerative colitis},
  language     = {eng},
  month        = {02},
  number       = {4},
  pages        = {825--833},
  publisher    = {Springer},
  series       = {Digestive Diseases and Sciences},
  title        = {Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease},
  url          = {http://dx.doi.org/10.1007/s10620-018-4971-1},
  volume       = {63},
  year         = {2018},
}